## Edgar Filing: GENEREX BIOTECHNOLOGY CORP - Form 3

#### GENEREX BIOTECHNOLOGY CORP

Form 3

August 30, 2007

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person \*

Masterson Nola E

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

05/29/2007

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

GENEREX BIOTECHNOLOGY CORP [GNBT]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O GENEREX **BIOTECHNOLOGY** CORPORATION. 33

HARBOUR SQUARE, STE 202

(Street)

(Check all applicable)

10% Owner \_X\_ Director Officer Other (give title below) (specify below)

6. Individual or Joint/Group

Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

TORONTO, Â A6Â M5J 2G2

(State)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security

(Instr. 4)

(City)

2. Amount of Securities Beneficially Owned

(Instr. 4)

Ownership Form:

4. Nature of Indirect Beneficial Ownership

(Instr. 5)

Direct (D) or Indirect

(Instr. 5)

No securities beneficially owned

 $0^{(1)}$ 

Â D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Zip)

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security** 

Ownership Conversion or Exercise

6. Nature of Indirect Beneficial Ownership

Form of (Instr. 5)

## Edgar Filing: GENEREX BIOTECHNOLOGY CORP - Form 3

Date Expiration Title Amount or Exercisable Date Shares Price of Derivative Security:

Output

Date Expiration Title Amount or Number of Shares

Output

Derivative Security:
Security Direct (D) or Indirect (I) (Instr. 5)

## **Reporting Owners**

Reporting Owner Name / Address

Director 10% Owner Officer Other

Masterson Nola E

C/O GENEREX BIOTECHNOLOGY CORPORATION 33 HARBOUR SQUARE, STE 202

TORONTO, A6Â M5J 2G2

# **Signatures**

/s/ Nola E.

Masterson

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) As of 5/29/2007, the date of the reporting person's election to the Board of Directors of Generex Biotechnology Corporation, the reporting person did not own any securities of Generex Biotechnology Corporation.

Â

#### **Remarks:**

1. Â As of 5/29/2007, the date of the reporting person's election to the Board of Directors of Ge Corporation, the reporting person did not own any securities of Generex Biotechnology Corporation.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2